Edesa Biotech (EDSA)
NASDAQ:EDSA
Want to see EDSA full AI Analyst Report?
EDSA Stock Chart & Stats
$1.48
>-$0.01(-0.02%)
At close: 4:00 PM EST
$1.48
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$0.72 - $20.32
Previous CloseN/A
Volume1.31K
Average Volume (3M)1.05M
Market Cap
$116.04M
Enterprise Value$98.91M
Total Cash (Recent Filing)$10.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.59
Next Earnings
Aug 07, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding8,891,951
10 Day Avg. Volume222,531
30 Day Avg. Volume1,052,222
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-960.45
Enterprise Value/Ebitda-9.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical DataStatistically significant Phase 3 mortality reduction materially lowers clinical and regulatory risk, supporting potential approvals and commercial opportunity. Provisional patents, government-funded trials and manufacturing scale-up cited alongside results bolster a credible path toward market readiness and durable value creation if approvals follow.
Low Financial LeverageEffectively zero debt and a tangible equity base reduce near-term solvency risk and preserve strategic optionality. Low leverage supports the company's ability to pursue additional trials or scale manufacturing without immediate debt servicing pressures, improving negotiating standing for partnerships or milestone-based financings over the medium term.
Cash-conservative Executive IncentivesShifting the CEO pay mix to equity reduces recurring cash payroll outflows and ties leadership incentives to long-term shareholder value. This conserves limited cash for R&D and operations and strengthens governance alignment, improving runway management and management-shareholder incentive congruence over the coming quarters.
Bears Say
High Cash BurnSizable negative operating and free cash flow is a structural constraint for a clinical-stage biotech. Persistent burn will steadily deplete cash reserves, forcing recurrent financing rounds that consume management time, increase dilution risk, and can delay or scale back pivotal programs if capital access tightens.
Minimal Commercial RevenueVirtually no product revenue and materially negative profitability indicate the company remains pre-commercial and dependent on successful trial outcomes. Until a product is approved and commercialized, margins will remain negative and the business model lacks recurring revenue, increasing execution and commercialization risk.
Reliance On External Equity FinancingDependence on equity and capital markets for operating cash is a structural vulnerability. Market volatility or tighter funding conditions can raise the cost of capital, accelerate dilution, or limit the timing and scope of development activities, directly impacting the company’s ability to advance multiple late-stage programs concurrently.
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech’s price range in the past 12 months?
Edesa Biotech lowest stock price was $0.72 and its highest was $20.32 in the past 12 months.
What is Edesa Biotech’s market cap?
Edesa Biotech’s market cap is $116.04M.
When is Edesa Biotech’s upcoming earnings report date?
Edesa Biotech’s upcoming earnings report date is Aug 07, 2026 which is in 81 days.
How were Edesa Biotech’s earnings last quarter?
Edesa Biotech released its earnings results on May 14, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.26 by -$0.23.
Is Edesa Biotech overvalued?
According to Wall Street analysts Edesa Biotech’s price is currently Overvalued.
Does Edesa Biotech pay dividends?
Edesa Biotech does not currently pay dividends.
What is Edesa Biotech’s EPS estimate?
Edesa Biotech’s EPS estimate is -0.55.
How many shares outstanding does Edesa Biotech have?
Edesa Biotech has 8,891,951 shares outstanding.
What happened to Edesa Biotech’s price movement after its last earnings report?
Edesa Biotech reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.26. Following the earnings report the stock price went down -10.678%.
Which hedge fund is a major shareholder of Edesa Biotech?
Currently, no hedge funds are holding shares in EDSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
EDSA Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $232.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 18.2%
Last 30 Days ▲ 18.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
162.38%
12-Months-Change
Fundamentals
Return on Equity
-78.94%
Trailing 12-Months
Asset Growth
-24.73%
Trailing 12-Months
Company Description
Edesa Biotech
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Ownership Overview
17.75% Insiders
0.86% Mutual Funds
24.25% Other Institutional Investors
56.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---